Multicenter clinical study with genetic polymorphisms analysis for the individualized antiemetic treatment.
Project/Area Number |
26860110
|
Research Category |
Grant-in-Aid for Young Scientists (B)
|
Allocation Type | Multi-year Fund |
Research Field |
Medical pharmacy
|
Research Institution | University of Shizuoka |
Principal Investigator |
Tsuji Daiki 静岡県立大学, 薬学部, 助教 (90565615)
|
Project Period (FY) |
2014-04-01 – 2016-03-31
|
Project Status |
Completed (Fiscal Year 2015)
|
Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2015: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2014: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
Keywords | グラニセトロン / パロノセトロン / アプレピタント / 遺伝子多型 / 制吐療法 / 薬物応答性 / オーダーメイド医療 / 化学療法誘発性悪心・嘔吐 |
Outline of Final Research Achievements |
This study evaluated the potential roles of pharmacogenomic polymorphisms in antiemetic treatment resistance in cancer patients previously enrolled in a randomized controlled trial (granisetron vs. palonosetron). A total of 156 patients treated with cisplatin-based chemotherapy were evaluated for their responses. In the granisetron group, the investigation of genetic polymorphisms on the pharmacokinetics of antiemetics showed that ABCB1 2677G>T/A and 3435C>T were associated with CR in overall phase. Multivariable logistic regression analysis revealed that the ABCB1 3435C>T polymorphism and cisplatin dose were significant predictors of CR. No association was found in palonosetron group. The investigation of genetic polymorphisms on the pharmacodynamics of antiemetics showed that ERCC1 8092 G>T and HT3D 107G>C were associated with CR in acute phase. The multivariate logistic regression analysis revealed that the ERCC1 8092TT and female were significant predictors of CR in acute phase.
|
Report
(3 results)
Research Products
(8 results)
-
[Journal Article] Influence of ABCB1 and ABCG2 polymorphisms on the antiemetic efficacy in patients with cancer receiving cisplatin-based chemotherapy: a TRIPLE pharmacogenomics study2016
Author(s)
Tsuji D, Yokoi M, Suzuki K, Daimon T, Nakao M, Ayuhara H, Kogure Y, Shibata K, Hayashi T, Hirai K, Inoue K, Hama T, Takeda K, Nishio M, Itoh K.
-
Journal Title
Pharmacogenomics J.
Volume: -
Related Report
Peer Reviewed / Acknowledgement Compliant
-
-
-
-
[Presentation] Influence of ABCB1 and ABCG2 polymorphisms on the antiemetic efficacy of a triple antiemetic combination in cancer patients receiving cisplatin-based chemotherapy: TRIPLE Pharmacogenomics Study2015
Author(s)
K. Suzuki, D. Tsuji, M. Yokoi, T. Daimon, M. Nakao, H. Ayuhara, Y. Kogure, K. Shibata, T. Hayashi, K. Takeda, M. Nishio, T. Hama, K. Itoh
Organizer
European Cancer Congress 2015
Place of Presentation
Vienna
Year and Date
2015-09-25 – 2015-09-29
Related Report
-
[Presentation] Influence of ABCB1 and ABCG2 polymorphisms on the antiemetic efficacy of triple antiemetic combination with aprepitant in cancer patients receiving cisplatin-based chemotherapy: TRIPLE Pharmacogenomics Study2015
Author(s)
Suzuki K, Tsuji D, Yokoi M, Daimon T, Nakao M, Ayuhara H, Kogure Y, Shibata K, Hayashi T, Hirai K, Inoue K, Hama T, Takeda K, Nishio M, Itoh K.
Organizer
European Cancer Congress 2015
Place of Presentation
Vienna
Year and Date
2015-09-25
Related Report
-
-